Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: ST-segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarction (NSTEMI) management has evolved considerably over the past 2 decades. Little information on mortality trends in the most recent years is available. We assessed trends in characteristics, treatments, and outcomes for acute myocardial infarction in France between 1995 and 2015.
Methods: We used data from 5 one-month registries, conducted 5 years apart, from 1995 to 2015, including 14 423 patients with acute myocardial infarction (59% STEMI) admitted to cardiac intensive care units in metropolitan France.
Results: From 1995 to 2015, mean age decreased from 66±14 to 63±14 years in patients with STEMI; it remained stable (68±14 years) in patients with NSTEMI, whereas diabetes mellitus, obesity, and hypertension increased. At the acute stage, intended primary percutaneous coronary intervention increased from 12% (1995) to 76% (2015) in patients with STEMI. In patients with NSTEMI, percutaneous coronary intervention ≤72 hours from admission increased from 9% (1995) to 60% (2015). Six-month mortality consistently decreased in patients with STEMI from 17.2% in 1995 to 6.9% in 2010 and 5.3% in 2015; it decreased from 17.2% to 6.9% in 2010 and 6.3% in 2015 in patients with NSTEMI. Mortality still decreased after 2010 in patients with STEMI without reperfusion therapy, whereas no further mortality gain was found in patients with STEMI with reperfusion therapy or in patients with NSTEMI, whether or not they were treated with percutaneous coronary intervention.
Conclusions: Over the past 20 years, 6-month mortality after acute myocardial infarction has decreased considerably for patients with STEMI and NSTEMI. Mortality figures continued to decline in patients with STEMI until 2015, whereas mortality in patients with NSTEMI appears stable since 2010.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.117.030798 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
5-HMF plays an intervention role in ischemic stroke by regulating GluR2 to improve mitochondrial function and promote angiogenesis.
Biochem Biophys Rep
December 2025
Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Introduction: 5-Hydroxymethyl furfural (5-HMF) is a furan compound with a molecular formula of CHO. Studies have found that 5-HMF has many pharmacological effects, such as improving hemorheology, anti-inflammatory, antioxidant activity and anti-myocardial ischemia. Identifying the preventive effect of 5-HMF against ischemic stroke and its possible mechanism was the aim of this investigation.
View Article and Find Full Text PDFThe Systemic Immune-Inflammation Index Predicts Long-Term Outcomes in Patients With Unstable Angina and Diabetes After Revascularization.
Rev Cardiovasc Med
August 2025
Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, 100029 Beijing, China.
Background: The incidence of unstable angina (UA), a type of cardiovascular disease (CVD), has increased in recent years. Meanwhile, timely percutaneous coronary intervention (PCI) or percutaneous transluminal coronary angioplasty (PTCA) procedures are crucial for patients with UA who also have diabetes mellitus (DM). Additionally, exploring other factors that may influence the prognosis of these patients could provide long-term benefits.
View Article and Find Full Text PDFTranscoronary Sinus Therapy for Coronary Microvascular Dysfunction.
Rev Cardiovasc Med
August 2025
Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.
Coronary microvascular disease has been found to increase the incidence of the composite endpoint for cardiovascular events and affect coronary revascularization. Coronary microvascular disease is often accompanied by epicardial disease, and despite successful revascularization and optimal medications, coronary microvascular disease may lead to reduced exercise tolerance and worsening clinical symptoms. Moreover, despite advances in percutaneous coronary intervention for coronary revascularization, the management of microvascular obstruction in reperfused myocardial tissue remains challenging and is a high-risk procedure.
View Article and Find Full Text PDFAssociation Between the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Adverse Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Study and Machine Learning Analysis.
Rev Cardiovasc Med
August 2025
Department of Cardiology, Xiamen Hospital of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, 361015 Xiamen, Fujian, China.
Background: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score represents a meaningful predictor in many cardiovascular diseases. However, the predictive utility of this score for the outcome of patients admitted to the intensive care unit (ICU) due to acute myocardial infarction (AMI) has yet to be fully elucidated.
Methods: Information from the Medical Information Mart for Intensive Care (MIMIC)-IV v3.
Association Between Admission Blood Pressure and In-hospital Mortality and Long-term Mortality of Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A China Acute Myocardial Infarction Registry Study.
Rev Cardiovasc Med
August 2025
Center for Coronary Heart Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases of China, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China.
Background: Globally, acute myocardial infarction (AMI) is among the primary causes of mortality. The ideal approach for blood pressure (BP) management for patients experiencing ST-segment elevation myocardial infarction (STEMI) who receive percutaneous coronary intervention (PCI) remains a topic of ongoing debate. Current guidelines on BP management lack specific recommendations for STEMI patients undergoing PCI, resulting in substantial individual variability and uncertainties in clinical treatment strategies.
View Article and Find Full Text PDF